Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Myeloma CAR-T update with Nina Shah

Nina Shah • 8 Jun 2020
EHA 2020
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel Orvacabtagene autoleucel
EVOLVE KarMMa

Nina Shah, MD, of the University of California, San Francisco, CA, discusses the advent of BCMA CAR-T therapy in multiple myeloma, highlighting data from the KarMMA trial (NCT03361748), updates with ciltacabtagene autoleucel (cilta-cel), and orvacabtagene autoleucel (orva-cel; NCT03430011). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nina Shah

Representation of women in hematology and oncology 2:07
Representation of women in hematology and oncology
Nina Shah • 15 Jun 2024
T-Cell Engagers: targets, challenges and opportunity 19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
NKTR-255 in multiple myeloma and NHL 1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
Reporting patient experiences during the KarMMa trial 2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals